Verastem (VSTM) Guggenheim Inaugural Global Healthcare Innovation Conference summary

Lead assets and clinical focus

• Lead program targets the RAS pathway with avutometinib (RAF/MEK clamp) plus a FAK inhibitor, aiming to overcome resistance in low-grade serous ovarian cancer (LGSOC).

• LGSOC is now recognized as a distinct disease, with Orphan Drug Designation and FDA recognition achieved in the past year.

• Standard treatments have low response rates (6%-13%) and short progression-free survival, highlighting unmet need.

• New therapy shows improved efficacy and tolerability, crucial for long-term treatment.

• Rolling NDA submission completed in October, with launch preparations for mid next year.

Diagnostic journey and market preparation

• LGSOC diagnosis is often delayed due to nonspecific symptoms and lack of awareness among providers.

• Efforts over 18 months have focused on raising awareness among patients and healthcare providers.

• Patient website and educational campaigns have been active to prepare the market for new therapy.

Competitive landscape and clinical data

• Off-label MEK inhibitors like trametinib are used minimally due to toxicity; binimetinib was inferior to standard care.

• Avutometinib plus defactinib shows better tolerability, with only 10% discontinuation due to adverse events.

• RAMP 201 study showed superior results in both KRAS mutant and wild-type patients, with KRAS mutation being a positive prognostic factor.

• Ongoing RAMP 301 phase III study is the first to prospectively stratify by KRAS status.